[미국특허]
Stinging cells expressing an exogenous polynucleotide encoding a therapeutic, diagnostic or a cosmetic agent and methods compositions and devices utilizing such stinging cells or capsules derived therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-009/00
A61K-009/70
C07H-021/04
C07H-021/00
출원번호
UP-0507692
(2003-03-20)
등록번호
US-7611723
(2009-11-16)
국제출원번호
PCT/IL03/000241
(2003-03-20)
§371/§102 date
20050616
(20050616)
국제공개번호
WO03/079967
(2003-10-02)
발명자
/ 주소
Lotan, Tamar
Eckhouse, Shimon
Shaoul, Esther
출원인 / 주소
NanoCyte Inc.
인용정보
피인용 횟수 :
3인용 특허 :
26
초록
A stinging cell comprising an exogenous polynucleotide capable of expressing a therapeutic, cosmetic or diagnostic agent in the stinging cell is provided.
대표청구항▼
What is claimed is: 1. A stinging cell or a stinging cell progenitor comprising an exogenous polynucleotide expressing a therapeutic, cosmetic or diagnostic agent in the stinging cell. 2. The stinging cell of claim 1, wherein said agent is a ribozyme and/or antisense polynucleotide. 3. The stin
What is claimed is: 1. A stinging cell or a stinging cell progenitor comprising an exogenous polynucleotide expressing a therapeutic, cosmetic or diagnostic agent in the stinging cell. 2. The stinging cell of claim 1, wherein said agent is a ribozyme and/or antisense polynucleotide. 3. The stinging cell of claim 1, wherein said agent is a polypeptide. 4. The stinging cell of claim 1, wherein said therapeutic agent is selected from the group consisting of a drug, a vaccine, a hormone, an enzyme and an antibody. 5. The stinging cell of claim 1, wherein said cosmetic agent is selected from the group consisting of an anti-wrinkling agent, an anti-acne agent, an exfoliant, a hair follicle stimulating agent and a hair follicle suppressing agent. 6. The stinging cell of claim 1, wherein said diagnostic agent is selected from the group consisting of a probe, a ligand, an antibody, a receptor and a receptor analog. 7. The stinging cell of claim 1, wherein said stinging cell is selected from the group consisting of a cnidocyte, a nematocyte, a spirocyte and a ptychocyte. 8. The stinging cell of claim 1, wherein said stinging cell or stinging cell progenitor is derived from an organism of a class selected from the group consisting of Anthozoa, Hydrozoa and Scyphozoa. 9. The stinging cell of claim 1, wherein said stinging cell or stinging cell progenitor is derived from an organism of a phylum selected from the group consisting of Cnidaria, Dinoflagelleaa and Myxozoa. 10. A composition comprising, as an active ingredient, a stinging cell expressing an exogenous polynucleotide encoding a therapeutic, cosmetic or diagnostic agent and a pharmaceutically acceptable carrier. 11. The composition of claim 10, wherein said agent is a ribozyme and/or antisense polynucleotide. 12. The composition of claim 10, wherein said agent is a polypeptide. 13. The composition of claim 10, wherein said therapeutic agent is selected from the group consisting of a drug, a vaccine, a hormone, an enzyme and an antibody. 14. The composition of claim 10, wherein said cosmetic agent is selected from the group consisting of an anti-wrinkling agent, an anti-acne agent, an exfoliant, a hair follicle stimulating agent and a hair follicle suppressing agent. 15. The composition of claim 10, wherein said diagnostic agent is selected from the group consisting of a probe, a ligand, an antibody, a receptor and a receptor analog. 16. The composition of claim 10, wherein said stinging cell is selected from the group consisting of a cnidocyte, a nematocyte, a spirocyte and a ptychocyte. 17. The composition of claim 10, wherein said stinging cell or stinging cell progenitor is derived from an organism of a class selected from the group consisting of Anthozoa, Hydrozoa and Scyphozoa. 18. The composition of claim 10, wherein said stinging cell or stinging cell progenitor is derived from an organism of a phylum selected from the group consisting of Cnidaria, Dinoflagellata and Myxozoa. 19. The composition of claim 10, wherein said pharmaceutically acceptable carrier is selected from the group consisting of an aqueous solution, a gel, an oil and a semisolid formulation. 20. The stinging cell of claim 1, wherein said exogenous polynucleotide is designed such that said therapeutic, cosmetic or diagnostic agent expressed therefrom accumulates in a stinging capsule portion of the stinging cell.
Eppstein Jonathan A. ; Hatch Michael R., Apparatus and method for electroporation of microporated tissue for enhancing flux rates for monitoring and delivery applications.
Wands Jack R. (Waban MA) Zurawski ; Jr. Vincent R. (West Chester PA) Schoemaker ; Hubert J. P. (Newton MA), Immunoassay utilizing monoclonal high affinity IgM antibodies.
Noonberg Sarah B. (Berkeley CA) Hunt C. Anthony (San Francisco CA), In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides deriv.
Smulson Mark E. (Washington DC) Bhatia Kishor (Arbutus MD) Huppi Konrad (Reston VA), Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for hu.
Lotan, Tamar; Eckhouse, Shimon, Methods compositions and devices utilizing stinging cells/capsules for delivering therapeutic or a cosmetic agent into a tissue.
Matner Richard R. (St. Paul MN) Foltz William E. (Cottage Grove MN) Woodson Lewis P. (Eagan MN), Rapid method for determining efficacy of a sterilization cycle and rapid read-out biological indicator.
Lotan, Tamar; Eckhouse, Shimon, Methods compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue.
Lotan, Tamar; Eckhouse, Shimon, Methods, compositions and devices utilizing stinging cells/capsules for conditioning a tissue prior to delivery of an active agent.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.